Corneal Defect Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of ZKY001 Eye Drops in Patients With Corneal Epithelial Defects After Corneal Endothelial Transplantation
The subjects of this study were patients who underwent corneal endothelial transplantation,who were randomly divided into 3 groups, 2 groups (0.002% and 0.004% ZKY001 eye drops) and 1 placebo control group.
This study is an exploratory phase II clinical study with no sample size estimation.According to the results of the preliminary animal experiments and phase I clinical trials, 2 concentrations (0.002% and 0.004%ZKY001eye drops) were selected as the experimental group, and 1 placebo control group was selected, with 35 subjects in each group and a total of 105 subjects.Each subject will drop the study drug into the test eye (the surgical eye is taken as the test eye) according to the randomly assigned drug number. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03662971 -
Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04521140 -
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery
|
Phase 4 | |
Completed |
NCT04975971 -
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
|
||
Recruiting |
NCT04626583 -
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
|
Phase 1 | |
Recruiting |
NCT05626478 -
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
|
Phase 4 | |
Recruiting |
NCT05204329 -
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
|
Early Phase 1 | |
Not yet recruiting |
NCT05458661 -
Feasibility Investigation of Biometry and Tomography Measurements in a Heterogeneous Patient Cohort
|
N/A | |
Completed |
NCT03967548 -
The Germinal Peptide Eye Drops in Healthy Volunteers in a Clinical Study
|
Phase 1 |